Psychiatry
Depressive Disorder
90
Pipeline Programs↗
5
Active Trials↗
45
Companies Involved↗
Depressive Disorder is a moderately active landscape with 90 programs across 45 companies. The most active players are Eastern Cooperative Oncology Group, Hyundai Pharmaceutical Co., LTD., Javelin Pharmaceuticals. 64 therapies are approved with 5 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Phase 15
Phase 28
Phase 35
Analysis
Trial Status
18
clinical trials
Completed7 · 39%
Recruiting4 · 22%
Unknown status3 · 17%
Terminated2 · 11%
Withdrawn1 · 6%
Active, not recruiting1 · 6%
Clinical Trials
Trial Activity
18 trials
Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders
Recruiting·—·N/A·NCT05962216·40 enrolled
The Measurement-based Care in Patients With Depressive Disorder: A Randomized Controlled Trial
Completed·—·Phase 4·NCT02191124·164 enrolled
Phenomenological Explorations of the Esketamine-Induced Transient Dissociative State
Completed·CCentre Hospitalier Intercommunal de Toulon La Seyne sur Mer·Preclinical·NCT06133309·15 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)